Technical Analysis for GOVX - GeoVax Labs, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | 0.54% | |
Stochastic Reached Oversold | Weakness | 0.54% | |
Inside Day | Range Contraction | 0.54% | |
Wide Bands | Range Expansion | 0.54% | |
Oversold Stochastic | Weakness | 0.54% | |
Wide Bands | Range Expansion | -2.63% |
Alert | Time |
---|---|
10 DMA Resistance | about 15 hours ago |
Fell Below Previous Day's Low | about 15 hours ago |
Down 1% | about 15 hours ago |
New 52 Week Low | about 15 hours ago |
Up 3% | about 19 hours ago |
Get a Trading Assistant
- Earnings date: 03/21/2024
GeoVax Labs, Inc. Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Infectious Diseases Immunotherapies Vaccines Allergy Hepatitis B Department Of Defense Viruses HIV Immunodeficiency Virus Malaria U.S. Department Of Defense Fever Virology Ebola Zika Chronic Hepatitis Scripps Vaccinia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.823 |
52 Week Low | 1.82 |
Average Volume | 45,512 |
200-Day Moving Average | 6.41 |
50-Day Moving Average | 2.72 |
20-Day Moving Average | 2.07 |
10-Day Moving Average | 1.92 |
Average True Range | 0.20 |
RSI (14) | 32.43 |
ADX | 30.91 |
+DI | 14.53 |
-DI | 24.22 |
Chandelier Exit (Long, 3 ATRs) | 2.24 |
Chandelier Exit (Short, 3 ATRs) | 2.42 |
Upper Bollinger Bands | 2.48 |
Lower Bollinger Band | 1.67 |
Percent B (%b) | 0.23 |
BandWidth | 39.33 |
MACD Line | -0.25 |
MACD Signal Line | -0.29 |
MACD Histogram | 0.038 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.00 | ||||
Resistance 3 (R3) | 2.01 | 1.96 | 1.97 | ||
Resistance 2 (R2) | 1.96 | 1.92 | 1.96 | 1.97 | |
Resistance 1 (R1) | 1.91 | 1.90 | 1.88 | 1.90 | 1.96 |
Pivot Point | 1.86 | 1.86 | 1.85 | 1.86 | 1.86 |
Support 1 (S1) | 1.81 | 1.83 | 1.79 | 1.80 | 1.74 |
Support 2 (S2) | 1.76 | 1.80 | 1.76 | 1.73 | |
Support 3 (S3) | 1.71 | 1.76 | 1.73 | ||
Support 4 (S4) | 1.70 |